Glomerulonephritis - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 124 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Glomerulonephritis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Glomerulonephritis - Pipeline Review, H2 2016', provides an overview of the Glomerulonephritis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Glomerulonephritis
- The report reviews pipeline therapeutics for Glomerulonephritis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Glomerulonephritis therapeutics and enlists all their major and minor projects
- The report assesses Glomerulonephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Glomerulonephritis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Glomerulonephritis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding  Glomerulonephritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Glomerulonephritis Overview 9
Therapeutics Development 10
Pipeline Products for Glomerulonephritis - Overview 10
Pipeline Products for Glomerulonephritis - Comparative Analysis 11
Glomerulonephritis - Therapeutics under Development by Companies 12
Glomerulonephritis - Therapeutics under Investigation by Universities/Institutes 15
Glomerulonephritis - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Glomerulonephritis - Products under Development by Companies 19
Glomerulonephritis - Products under Investigation by Universities/Institutes 21
Glomerulonephritis - Companies Involved in Therapeutics Development 22
Achillion Pharmaceuticals, Inc. 22
Alexion Pharmaceuticals Inc 23
Amyndas Pharmaceuticals LLC 24
Anthera Pharmaceuticals Inc 25
Avexxin AS 26
Biogen Inc 27
Complexa, Inc. 28
Dimerix Bioscience Pty Ltd 29
GlaxoSmithKline Plc 30
Mallinckrodt Plc 31
Omeros Corporation 32
Pfizer Inc. 33
Pharmalink AB 34
Retrophin Inc. 35
Rigel Pharmaceuticals, Inc. 36
Shire Plc 37
Toray Industries, Inc. 38
Variant Pharmaceuticals, Inc. 39
Glomerulonephritis - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Combination Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
(irbesartan + propagermanium) - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
ACH-4471 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
AMY-101 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
AVX-002 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
belimumab - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
blisibimod - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
budesonide - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
corticotropin - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
CXA-10 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
eculizumab - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
fostamatinib disodium - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
losmapimod - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Monoclonal Antibodies to Inhibit Glycoprotein Ib Alpha for Vasculitis and Glomerulonephritis - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
OMS-721 - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
PF-1355 - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
Recombinant Enzyme for Immunoglobulin A Nephropathy - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
rituximab - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
SHP-627 - Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
Small Molecule to Inhibit Vitamin K Epoxide Reductase for Glomerulonephritis - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
sparsentan - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
TM-5484 - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
VAR-200 - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
Glomerulonephritis - Dormant Projects 111
Glomerulonephritis - Discontinued Products 113
Glomerulonephritis - Product Development Milestones 114
Featured News & Press Releases 114
Aug 01, 2016: Dimerix announces outcomes of DMX-200 pre-IND meeting with the FDA 114
May 17, 2016: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Rare Cause of Nephrotic Syndrome 115
Mar 30, 2016: Retrophin Completes Enrollment of Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis 115
Mar 04, 2016: Amyndas' lead candidate AMY-101 receives orphan drug status from the FDA and the EMA for the treatment of C3 glomerulopathy 116
Dec 14, 2015: Dimerix receives Orphan Designation for its lead drug candidate targeting patients with chronic kidney disease 116
Nov 16, 2015: Retrophin Receives European Orphan Drug Designation for Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis 117
Jan 09, 2015: Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan 117
Feb 25, 2013: Ligand Receives $1.4m Milestone Payment From Retrophin 118
Jan 09, 2013: Ligand Receives Equity Milestone Payment From Retrophin 118
Oct 31, 2012: Pharmalink Signs Manufacturing Agreement For Nefecon 119
Oct 13, 2010: Pharmalink Receives US Orphan Drug Designation For Nefecon 120
Oct 26, 2009: Japanese Patent granted for Pharmalink AB's Nefecon 120
Apr 29, 2009: Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon 121
Mar 31, 2008: Pharmalink Reports Promising Interim Results From Phase II Trials For New Renal Disease Drug Nefecon 121
Appendix 123
Methodology 123
Coverage 123
Secondary Research 123
Primary Research 123
Expert Panel Validation 123
Contact Us 123
Disclaimer 124

List of Tables

Number of Products under Development for Glomerulonephritis, H2 2016 10
Number of Products under Development for Glomerulonephritis - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Development by Companies, H2 2016 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2016 21
Glomerulonephritis - Pipeline by Achillion Pharmaceuticals, Inc., H2 2016 22
Glomerulonephritis - Pipeline by Alexion Pharmaceuticals Inc, H2 2016 23
Glomerulonephritis - Pipeline by Amyndas Pharmaceuticals LLC, H2 2016 24
Glomerulonephritis - Pipeline by Anthera Pharmaceuticals Inc, H2 2016 25
Glomerulonephritis - Pipeline by Avexxin AS, H2 2016 26
Glomerulonephritis - Pipeline by Biogen Inc, H2 2016 27
Glomerulonephritis - Pipeline by Complexa, Inc., H2 2016 28
Glomerulonephritis - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016 29
Glomerulonephritis - Pipeline by GlaxoSmithKline Plc, H2 2016 30
Glomerulonephritis - Pipeline by Mallinckrodt Plc, H2 2016 31
Glomerulonephritis - Pipeline by Omeros Corporation, H2 2016 32
Glomerulonephritis - Pipeline by Pfizer Inc., H2 2016 33
Glomerulonephritis - Pipeline by Pharmalink AB, H2 2016 34
Glomerulonephritis - Pipeline by Retrophin Inc., H2 2016 35
Glomerulonephritis - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 36
Glomerulonephritis - Pipeline by Shire Plc, H2 2016 37
Glomerulonephritis - Pipeline by Toray Industries, Inc., H2 2016 38
Glomerulonephritis - Pipeline by Variant Pharmaceuticals, Inc., H2 2016 39
Assessment by Monotherapy Products, H2 2016 40
Assessment by Combination Products, H2 2016 41
Number of Products by Stage and Target, H2 2016 43
Number of Products by Stage and Mechanism of Action, H2 2016 45
Number of Products by Stage and Route of Administration, H2 2016 47
Number of Products by Stage and Molecule Type, H2 2016 49
Glomerulonephritis - Dormant Projects, H2 2016 111
Glomerulonephritis - Dormant Projects (Contd..1), H2 2016 112
Glomerulonephritis - Discontinued Products, H2 2016 113